1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. California >
  6. Biogen Acquires HI-Bio

M&A Deal Summary

Biogen Acquires HI-Bio

On May 22, 2024, Biogen acquired life science company HI-Bio

Acquisition Highlights
  • This is Biogen’s 9th transaction in the Life Science sector.
  • This is Biogen’s 6th transaction in the United States.
  • This is Biogen’s 1st transaction in California.

M&A Deal Summary
Date 2024-05-22
Target HI-Bio
Sector Life Science
Buyer(s) Biogen
Deal Type Add-on Acquisition

Target

HI-Bio

South San Francisco, California, United States
HI-Bio is a clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases (IMDs). The company’s felzartamab is a CD38-targeted antibody shown in clinical studies to deplete CD38+ cells, including plasma and natural killer (NK) cells, which are implicated in a range of indications including antibody-mediated rejection (AMR), IgA nephropathy (IgAN), lupus nephritis (LN) and primary membranous nephropathy (PMN). HI-Bio is based in South San Francisco, California.

Search 215,058 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Biogen

Cambridge, Massachusetts, United States
Category Company
Founded 1978
Sector Life Science
Employees7,605
Revenue 9.7B USD (2024)
DESCRIPTION
Entrance to Biogen office in Weston, Massachusetts.
Entrance to Biogen office in Weston, Massachusetts.

Biogen is a biopharmaceutical company focused on discovering, developing, and delivering worldwide therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Biogen was founded in 1978 and is based in Cambridge, Massachusetts.

DEAL STATS #
Overall 9 of 10
Sector: Life Science M&A 9 of 10
Type: Add-on Acquisition M&A Deals 7 of 8
State: California M&A 1 of 1
Country: United States M&A 6 of 7
Year: 2024 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2023-07-28 Reata

Plano, Texas, United States

Reata engages in developing novel oral anti-inflammatory drugs targeting NrF2. This important biological target has been shown to protect against a broad range of diseases associated with inflammation and oxidative stress. Reata was founded in 2002 and is based in Plano, Texas.

Buy $7.3B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2025-11-14 Alcyone Therapeutics

Lowell, Massachusetts, United States

Alcyone Therapeutics develops precision gene-based therapies for complex neurological conditions, with an emphasis on intrathecal delivery and cerebrospinal fluid-based dosing technologies. Alcyone Therapeutics was founded in 2012 and is headquartered in Lowell, Massachusetts.

Buy -
Mergr

Solution for

Product

Company

Legal